Medical Monitor
Incyte Corporation · Astellas Pharma Global Development, Inc. · Denali Therapeutics Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Medical Monitor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:47 UTC. Showing 200 of 1897. Open this list on ClinicalTrials.gov
- Ph2NCT07862998 · A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic TherapyIncyte Corporation · not yet recruiting · Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma · study director
- Ph1NCT07854249 · A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on HemodialysisIncyte Corporation · not yet recruiting · Renal Insufficiency, Kidney Diseases · study director
- Ph1NCT07853040 · A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentIncyte Corporation · not yet recruiting · Hepatic Insufficiency, Liver Diseases · study director
- Ph4NCT07829757 · A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric CancerAstellas Pharma Global Development, Inc. · not yet recruiting · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer · study director
- Ph2NCT07823322 · A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and ChemotherapyIncyte Corporation · not yet recruiting · CRC (Colorectal Cancer) · study director
- Ph1NCT07814404 · A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph3NCT07797283 · Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1Incyte Corporation · not yet recruiting · Ovarian Cancer · study director
- Ph1NCT07783282 · A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerAstellas Pharma Global Development, Inc. · recruiting · Prostate Cancer · study director
- Ph1NCT07758595 · A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's DiseaseDenali Therapeutics Inc. · recruiting · Alzheimer's Disease, Healthy Participants · study director
- Ph1/Ph2NCT07730021 · A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsAstellas Pharma Global Development, Inc. · recruiting · Locally Advanced or Metastatic Solid Tumors · study director
- Ph1/Ph2NCT07660614 · A Study of LTX-002 in Adult Participants With Amyotrophic Lateral SclerosisLeal Therapeutics, Inc · recruiting · Amyotrophic Lateral Sclerosis · study director
- Ph3NCT07623200 · A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaIncyte Corporation · recruiting · Essential Thrombocythemia · study director
- Ph1NCT07588139 · A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT07559396 · A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal DiseaseIncyte Corporation · recruiting · Renal Impairment · study director
- Ph1NCT07559474 · A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentIncyte Corporation · recruiting · Hepatic Insufficiency, Liver Diseases · study director
- Ph3NCT07522073 · A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaIncyte Corporation · recruiting · Solid Tumors · study director
- Ph3NCT07480564 · Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett SyndromeTaysha Gene Therapies, Inc. · active not recruiting · Rett Syndrome · study director
- Ph1NCT07448155 · A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsIncyte Corporation · active not recruiting · Healthy Participants · study director
- Ph1NCT07441694 · Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation · recruiting · Myeloproliferative Neoplasms · study director
- Ph1NCT07354724 · A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe DiseaseDenali Therapeutics Inc. · recruiting · Late-onset Pompe Disease · study director
- N/ANCT07338968 · A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal MelanomaAura Biosciences · enrolling by invitation · Choroidal Melanoma, Indeterminate Lesions · study director
- Ph1NCT07328451 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's DiseaseDenali Therapeutics Inc. · recruiting · Alzheimer Disease, Early Onset · study director
- Ph1/Ph2NCT07287995 · A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsAstellas Pharma Global Development, Inc. · recruiting · Locally Advanced or Metastatic Malignant Solid Tumors · study director
- Ph3NCT07284849 · A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerIncyte Corporation · recruiting · CRC (Colorectal Cancer) · study director
- Ph1NCT07218744 · Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph2NCT07213973 · Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaIncyte Corporation · recruiting · Hidradenitis Suppurativa (HS) · study director
- Ph3NCT07214779 · Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionIncyte Corporation · recruiting · Ovarian Cancer · study director
- Ph1NCT07140016 · A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc. · recruiting · Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive · study director
- Ph2NCT07124078 · A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)Incyte Corporation · recruiting · Chronic Graft-versus-host-disease · study director
- Ph2NCT07104565 · Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation · recruiting · Immune Thrombocytopenia · study director
- Ph1NCT07049575 · Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaIncyte Corporation · recruiting · Hidradenitis Suppurativa · study director
- Ph1NCT07039929 · Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult ParticipantsIncyte Corporation · terminated · Healthy Participants · study director
- Ph2NCT07023627 · A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionIncyte Corporation · recruiting · Ovarian Cancer · study director
- Ph1NCT07018635 · A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT07008118 · A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsIncyte Corporation · recruiting · Myeloproliferative Neoplasms · study director
- Ph2NCT07005154 · A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerAstellas Pharma Global Development, Inc. · recruiting · Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer · study director
- Ph1/Ph2NCT07006805 · RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisCabaletta Bio · withdrawn · Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting · study chair
- Ph1/Ph2NCT06980948 · Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)Sangamo Therapeutics · suspended · Chronic Neuropathic Pain · study director
- N/ANCT06934980 · A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis ParticipantsIncyte Corporation · completed · Atopic Dermatitis, Healthy Volunteers · study director
- Ph1NCT06909162 · A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph3NCT06901531 · A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerAstellas Pharma Global Development, Inc. · recruiting · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer · study director
- Ph1/Ph2NCT06873789 · A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsIncyte Corporation · terminated · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors · study director
- Ph4NCT06862219 · A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerAstellas Pharma Global Development, Inc. · recruiting · Metastatic Urothelial Carcinoma · study director
- Ph3NCT06855498 · Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibIncyte Corporation · recruiting · Hidradenitis Suppurativa (HS) · study director
- Ph1/Ph2NCT06843408 · A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDIncyte Corporation · active not recruiting · Chronic Graft-versus-host-disease · study director
- Ph3NCT06832618 · A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisIncyte Corporation · active not recruiting · Atopic Dermatitis · study director
- Ph3NCT06821542 · A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyIncyte Corporation · active not recruiting · Chronic Graft-versus-host-disease · study director
- Ph1NCT06818812 · A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationIncyte Corporation · active not recruiting · Solid Tumors · study director
- Ph3NCT06804811 · A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoIncyte Corporation · recruiting · NonSegmental Vitiligo · study director
- Ph1NCT06775327 · Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT06713590 · A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT06681870 · A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid TumorsAstellas Pharma Global Development, Inc. · withdrawn · CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer · study director
- Ph1NCT06680232 · Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis BPrecision BioSciences, Inc. · recruiting · HEPATITIS B CHRONIC · study director
- Ph2NCT06643884 · Suprachoroidal Administration in Subjects With Metastases to the ChoroidAura Biosciences · recruiting · Eye Cancer, Primary Cancer · study director
- N/ANCT06627335 · An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisIncyte Corporation · recruiting · Pregnancy Related, Atopic Dermatitis · study director
- Ph3NCT06615050 · A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)Incyte Corporation · recruiting · Graft-versus-host Disease (GVHD) · study director
- Ph1NCT06555081 · A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph3NCT06548360 · A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoIncyte Corporation · recruiting · NonSegmental Vitiligo · study director
- Ph3NCT06516952 · A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Incyte Corporation · active not recruiting · Prurigo Nodularis · study director
- Ph3NCT06516965 · A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Incyte Corporation · active not recruiting · Prurigo Nodularis · study director
- Ph1NCT06505265 · A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT06441318 · A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT06416800 · A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult ParticipantsIncyte Corporation · completed · Healthy Participants · study director
- Ph2NCT06388564 · A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseIncyte Corporation · active not recruiting · Chronic Graft-versus-host-disease · study director
- Ph1NCT06380205 · A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesIncyte Corporation · completed · Healthy Participants · study director
- Ph1NCT06310304 · A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.Incyte Corporation · completed · Healthy Participants · study director
- Ph1NCT06270706 · A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPliant Therapeutics, Inc. · recruiting · Advanced or Metastatic Solid Tumor · study director
- Ph3NCT06263478 · A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host DiseaseIncyte Biosciences Japan GK · active not recruiting · Chronic Graft-versus-host-disease · study director
- Ph3NCT06238817 · A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisIncyte Corporation · completed · Atopic Dermatitis · study director
- Ph3NCT06224907 · Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia ABioMarin Pharmaceutical · active not recruiting · Hemophilia A · study director
- Ph3NCT06212999 · A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaIncyte Corporation · active not recruiting · Hidradenitis Suppurativa (HS) · study director
- Ph1NCT06213831 · A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamIncyte Corporation · completed · Prurigo Nodularis · study director
- Ph1NCT06179160 · A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationIncyte Corporation · recruiting · Solid Tumors · study director
- Ph3NCT06113445 · A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Incyte Corporation · active not recruiting · NonSegmental Vitiligo · study director
- Ph3NCT06113471 · A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Incyte Corporation · active not recruiting · NonSegmental Vitiligo · study director
- Ph2NCT06097260 · Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisPliant Therapeutics, Inc. · terminated · Idiopathic Pulmonary Fibrosis · study director
- Ph3NCT06072781 · A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerVerastem, Inc. · recruiting · Low Grade Serous Ovarian Cancer · study director
- Ph2/Ph3NCT06075537 · An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007Denali Therapeutics Inc. · enrolling by invitation · Mucopolysaccharidosis II · study director
- Ph1NCT06039384 · A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationIncyte Corporation · terminated · Advanced Solid Tumors · study director
- Ph1NCT06034002 · A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsIncyte Corporation · recruiting · Myeloproliferative Neoplasms · study director
- Ph3NCT06007690 · A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaAura Biosciences · active not recruiting · Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma · study director
- Ph3NCT05999747 · A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney DiseaseAstellas Pharma Global Development, Inc. · completed · Intraoperative Ureter Visualization, Abdominolpelvic Surgery · study director
- Ph1NCT05997615 · Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerAstellas Pharma Global Development, Inc. · recruiting · Hormone-refractory Prostate Cancer · study director
- Ph3NCT05970172 · A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseaseAstellas Pharma Global Development, Inc. · active not recruiting · Chronic Kidney Disease, Renal Anemia · study director
- Ph1NCT05936359 · A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsIncyte Corporation · active not recruiting · Myeloproliferative Neoplasms · study director
- Ph2NCT05906628 · Topical Ruxolitinib Evaluation in Chronic Hand EczemaIncyte Corporation · completed · Hand Eczema · study director
- Ph2NCT05888844 · A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaIncyte Corporation · terminated · Cutaneous Squamous Cell Carcinoma · study director
- Ph2NCT05879822 · A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveIncyte Corporation · terminated · Advanced Solid Tumor · study director
- Ph3NCT05754333 · A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During SurgeryAstellas Pharma Global Development, Inc. · completed · Intraoperative Ureter Visualization, Abdominolpelvic Surgery · study director
- Ph1NCT05653882 · A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsAsher Biotherapeutics, Inc. · active not recruiting · Solid Tumor, Non Small Cell Lung Cancer, Melanoma · study director
- Ph3NCT05606614 · A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)Taysha Gene Therapies, Inc. · active not recruiting · Rett Syndrome · study director
- Ph1NCT05483868 · A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerAura Biosciences · active not recruiting · Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma · study director
- N/ANCT05467176 · A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXSumitomo Pharma America, Inc. · completed · Prostate Cancer · study director
- N/ANCT05462054 · Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with EpilepsyCapsida Biotherapeutics, Inc. · withdrawn · STXBP1 Encephalopathy with Epilepsy · study director
- Ph2NCT05457842 · A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During SurgeryAstellas Pharma Inc · terminated · Sentinel Lymph Node Biopsy, Breast Cancer, Melanoma · study director
- N/ANCT05266430 · Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)Aura Biosciences · terminated · Choroidal Melanoma, Indeterminate Lesions · study director
- Ph4NCT05165485 · Phase 4 COPD and Suboptimal Inspiratory Flow RateTheravance Biopharma · completed · Chronic Obstructive Pulmonary Disease · study director
- Ph2/Ph3NCT05158296 · Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)Laboratoires Thea · terminated · Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind · study director
- N/ANCT05145062 · Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.Sangamo Therapeutics · active not recruiting · Blood and Lymphatic Diseases · study director
- Ph1NCT05091723 · TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationTheravance Biopharma · completed · Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) · study director
- Ph3NCT05092360 · Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)Mural Oncology, Inc · terminated · Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer · study director
- Ph2NCT05085964 · An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis PigmentosaLaboratoires Thea · terminated · Retinitis Pigmentosa, Usher Syndrome Type 2 · study director
- Ph1NCT05052554 · Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3ProQR Therapeutics · withdrawn · Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases · study director
- N/ANCT05039866 · Long-Term Follow-up of Subjects Who Were Treated With ST-920Sangamo Therapeutics · active not recruiting · Fabry Disease, Fabry Disease, Cardiac Variant · study director
- Ph2NCT05038020 · A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)Alkahest, Inc. · terminated · Diabetic Retinopathy · study director
- N/ANCT04985383 · Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on HemodialysisAlkahest, Inc. · completed · End-Stage Renal Disease · study director
- Ph2/Ph3NCT04855045 · An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.ProQR Therapeutics · unknown · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis · study director
- Ph1NCT04836494 · A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic AcidemiaCoA Therapeutics, Inc., a BridgeBio company · terminated · Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia · study chair
- Ph2NCT04830124 · Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6Mural Oncology, Inc · terminated · Cutaneous Melanoma, Mucosal Melanoma · study director
- Ph2NCT04826172 · Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)Imbria Pharmaceuticals, Inc. · completed · Ischemia, Coronary Artery Disease · study chair
- Ph2NCT04826185 · A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy TrialImbria Pharmaceuticals, Inc. · completed · Non-obstructive Hypertrophic Cardiomyopathy · study chair
- Ph2NCT04785365 · Long-Term Follow-Up Study of Patients Receiving ATL001Achilles Therapeutics UK Limited · terminated · Melanoma, Advanced Non Small Cell Lung Cancer · study director
- Ph1NCT04714554 · A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult MenMyovant Sciences GmbH · completed · Healthy · study director
- Ph1NCT04688632 · Thorough QT Study to Evaluate Ampreloxetine in Healthy SubjectsTheravance Biopharma · completed · Symptomatic Neurogenic Orthostatic Hypertension, nOH · study director
- Ph1/Ph2NCT04684940 · Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsBioMarin Pharmaceutical · completed · Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII · study director
- N/ANCT04681079 · Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19Theravance Biopharma · completed · COVID-19 · study director
- N/ANCT04645212 · Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Adverum Biotechnologies, Inc. · active not recruiting · Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration · study director
- Ph3NCT04641975 · A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)Astellas Pharma Global Development, Inc. · terminated · Overactive Bladder (OAB), Pharmacokinetics of Mirabegron · study director
- N/ANCT04628871 · Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIXSangamo Therapeutics · terminated · Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II · study director
- Ph1NCT04594031 · US Phase I Study of ECT-001-CB in Patients With Sickle-Cell DiseaseExCellThera inc. · withdrawn · Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation · study director
- Ph1NCT04589260 · TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary FibrosisTheravance Biopharma · terminated · Idiopathic Pulmonary Fibrosis (IPF) · study director
- Ph1/Ph2NCT04592653 · Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Mural Oncology, Inc · active not recruiting · Advanced Solid Tumor · study director
- Ph2NCT04584710 · A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsRestorbio Inc. · active not recruiting · Covid19 · study director
- N/ANCT04527328 · A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive ImpairmentAlkahest, Inc. · completed · Cognitive Impairment, End Stage Renal Disease · study director
- Ph2NCT04499235 · A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous PemphigoidAlkahest, Inc. · terminated · Pemphigoid, Bullous · study director
- Ph2NCT04480840 · Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)Pliant Therapeutics, Inc. · completed · Primary Sclerosing Cholangitis · study director
- Ph2NCT04434937 · Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)Incyte Biosciences Japan GK · completed · Lymphoma · study director
- Ph2NCT04418427 · ADVM-022 Intravitreal Gene Therapy for DMEAdverum Biotechnologies, Inc. · completed · Diabetic Macular Edema, Diabetic Retinopathy · study chair
- Ph2NCT04417530 · Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MelanomaAura Biosciences · completed · Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma · study director
- Ph2NCT04402866 · TD-0903 for ALI Associated With COVID-19Theravance Biopharma · completed · Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 · study director
- Ph2NCT04396756 · Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisPliant Therapeutics, Inc. · completed · Idiopathic Pulmonary Fibrosis · study director
- Ph2NCT04369430 · Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentAlkahest, Inc. · completed · Parkinson Disease · study director
- Ph1NCT04350736 · First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19Theravance Biopharma · completed · Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19 · study director
- N/ANCT04349956 · Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or PlaceboUnity Biotechnology, Inc. · terminated · Knee Osteoarthritis · study director
- Ph2NCT04331730 · A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMDAlkahest, Inc. · completed · Neovascular Age-related Macular Degeneration · study director
- Ph3NCT04323098 · Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ABioMarin Pharmaceutical · completed · Hemophilia A · study director
- Ph1NCT04242199 · Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsIncyte Corporation · completed · Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma · study director
- Ph2NCT04238481 · A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal SurgeryAstellas Pharma Inc · completed · Laparoscopic/Minimally Invasive Colorectal Surgery · study director
- Ph3NCT04234204 · A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through MenopauseAstellas Pharma China, Inc. · completed · Hot Flashes · study director
- Ph1NCT04229225 · A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the KneeUnity Biotechnology, Inc. · completed · Knee Osteoarthritis · study director
- Ph3NCT04205812 · Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerIncyte Corporation · completed · Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer · study director
- Ph3NCT04203511 · INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)Incyte Corporation · withdrawn · Non-small Cell Lung Cancer · study director
- N/ANCT04201782 · Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-TSangamo Therapeutics · terminated · HIV-1-infection · study director
- Ph1NCT04200573 · Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855Theravance Biopharma · completed · Symptomatic Neurogenic Orthostatic Hypertension, nOH · study director
- Ph1NCT04155710 · Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLIovance Biotherapeutics, Inc. · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · study chair
- Ph2NCT04150341 · Effect of Inhaled TD-8236 on Allergen-induced Asthmatic ResponseTheravance Biopharma · completed · Asthma · study director
- Ph2NCT04129944 · A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the KneeUnity Biotechnology, Inc. · completed · Osteoarthritis, Knee · study director
- Ph1/Ph2NCT04123626 · A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO GeneProQR Therapeutics · active not recruiting · Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary · study director
- Ph1NCT04121676 · Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerAgenus Inc. · completed · Advanced Cancer · study director
- Ph3NCT04095793 · Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance Biopharma · terminated · Symptomatic Neurogenic Orthostatic Hypotension · study director
- Ph2NCT04072315 · Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/Pliant Therapeutics, Inc. · completed · Idiopathic Pulmonary Fibrosis · study director
- Ph1/Ph2NCT04046224 · Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)Sangamo Therapeutics · completed · Fabry Disease · study director
- Ph1NCT04044339 · Single and Multiple Ascending Dose, First-in- Human Study in Healthy SubjectsTheravance Biopharma · completed · Healthy · study director
- Ph1/Ph2NCT04032847 · ATL001 in Patients With Advanced Unresectable or Metastatic NSCLCAchilles Therapeutics UK Limited · terminated · Advanced Non Small Cell Lung Cancer · study director
- Ph2NCT04003623 · Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)Incyte Corporation · terminated · Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations · study director
- Ph1/Ph2NCT03997474 · ATL001 in Patients With Metastatic or Recurrent MelanomaAchilles Therapeutics UK Limited · terminated · Melanoma · study director
- Ph2NCT03981419 · A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee ArthroplastyAlkahest, Inc. · completed · Postoperative Recovery · study director
- N/ANCT03941379 · A Registry of Subjects With Primary Indeterminate Lesions or Choroidal MelanomaAura Biosciences · active not recruiting · Choroidal Melanoma, Indeterminate Lesions of Eye · study director
- Ph1NCT03920839 · INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)Incyte Corporation · withdrawn · Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma · study director
- Ph2/Ph3NCT03913143 · A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)ProQR Therapeutics · active not recruiting · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis · study director
- Ph1/Ph2NCT03910660 · A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma PhenotypeBioXcel Therapeutics Inc · completed · Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma · study director
- Ph3NCT03852719 · Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)Gilead Sciences · completed · Chronic Hepatitis Delta · study chair
- Ph2NCT03852433 · Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)Gilead Sciences · completed · Chronic Hepatitis Delta · study chair
- Ph3NCT03829657 · Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance Biopharma · terminated · Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD) · study director
- Ph1NCT03799003 · A Study of ASP1951 in Subjects With Advanced Solid TumorsAstellas Pharma Global Development, Inc. · terminated · Advanced Solid Tumors · study director
- Ph2NCT03784287 · A Treatment Extension Study of Mucopolysaccharidosis Type IIIBAllievex Corporation · unknown · Mucopolysaccharidosis Type IIIB, MPS III B · study director
- Ph1/Ph2NCT03780257 · Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GeneProQR Therapeutics · completed · Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind · study director
- Ph2/Ph3NCT03758443 · Efficacy & Safety of TD-1473 in Ulcerative ColitisTheravance Biopharma · terminated · Ulcerative Colitis (UC) · study director
- Ph1NCT03755713 · A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid VaccineAstellas Pharma Global Development, Inc. · completed · Peanut Allergy · study director
- Ph3NCT03750552 · Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance Biopharma · completed · Symptomatic Neurogenic Orthostatic Hypotension · study director
- Ph1NCT03750565 · Multiple Dose Ethnobridging PK Study in Healthy SubjectsTheravance Biopharma · completed · Inflammatory Bowel Diseases, IBD · study director
- Ph1NCT03748784 · ADVM-022 Intravitreal Gene Therapy for Wet AMDAdverum Biotechnologies, Inc. · completed · Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration · study chair
- Ph4NCT03737708 · A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)Astellas Pharma Korea, Inc. · completed · Rheumatoid Arthritis (RA) · study director
- Ph2NCT03713957 · A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentAlkahest, Inc. · completed · Parkinson Disease · study director
- Ph1NCT03698305 · A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging ProductAstellas Pharma Global Development, Inc. · completed · Healthy Subjects · study director
- Ph3NCT03660059 · A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)Astellas Pharma China, Inc. · completed · Rheumatoid Arthritis (RA) · study director
- Ph3NCT03654274 · SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated PainMyovant Sciences GmbH · completed · Endometriosis · study director
- Ph1/Ph2NCT03653247 · A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseSangamo Therapeutics · completed · Sickle Cell Disease · study director
- Ph1NCT03652038 · Single and Multiple Ascending Dose Study of TD-8236 by InhalationTheravance Biopharma · completed · Asthma · study director
- Ph2NCT03646123 · Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaSeagen Inc. · terminated · Hodgkin Lymphoma · study director
- Ph2NCT03645928 · Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsIovance Biotherapeutics, Inc. · terminated · Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer · study director
- Ph2NCT03635112 · Efficacy and Safety of TD-1473 in Crohn's DiseaseTheravance Biopharma · terminated · Crohn's Disease · study director
- Ph2NCT03599713 · A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)Incyte Corporation · completed · Metastatic Merkel Cell Carcinoma · study director
- Ph2NCT03597295 · A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)Incyte Corporation · completed · Squamous Cell Carcinoma of Anal Canal · study director
- Ph3NCT03573817 · A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDMylan Inc. · completed · Chronic Obstructive Pulmonary Disease (COPD) · study director
- Ph1NCT03565445 · A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsAstellas Pharma Global Development, Inc. · completed · Advanced Solid Tumors · study director
- Ph2NCT03558061 · Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular DegenerationAlkahest, Inc. · completed · Wet Age-related Macular Degeneration · study director
- Ph2NCT03558074 · Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular DegenerationAlkahest, Inc. · completed · Wet Age-related Macular Degeneration · study director
- Ph1NCT03555617 · Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging StudyTheravance Biopharma · completed · Inflammatory Bowel Disease · study director
- Ph2NCT03520998 · A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's DiseaseAlkahest, Inc. · completed · Alzheimer Disease, Mild to Moderate Alzheimer Disease · study director
- N/ANCT03506386 · Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational AnalysisTakeda · completed · Multiple Myeloma · study director
- Ph3NCT03500094 · Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)Amicus Therapeutics · completed · Fabry Disease · study director
- Ph1/Ph2NCT03432364 · A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)Sangamo Therapeutics · completed · Transfusion Dependent Beta-thalassemia · study director
- Ph1NCT03432793 · Drug-Drug Interaction (DDI) Study for TD-9855Theravance Biopharma · completed · Drug Drug Interaction (DDI) · study director
- Ph2NCT03419559 · Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerIovance Biotherapeutics, Inc. · withdrawn · Non Small Cell Lung Cancer · study director
- Ph2NCT03418571 · Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract InfectionAblynx, a Sanofi company · terminated · Respiratory Syncytial Virus Lower Respiratory Tract Infection · study director
- Ph1NCT03415126 · A Study of ASN007 in Patients With Advanced Solid TumorsAsana BioSciences · completed · Cancer, Malignancy, Neoplasia · study director
- Ph3NCT03412890 · LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsMyovant Sciences GmbH · completed · Heavy Menstrual Bleeding, Uterine Fibroid · study director
- Ph1NCT03408470 · TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsTheravance Biopharma · completed · Intestinal Disorders, Bowel Diseases, Inflammatory · study director
- Ph3NCT03370913 · Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)BioMarin Pharmaceutical · completed · Hemophilia A · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- mTOR Regulation of Basal Antiviral Immunity in the ElderlyR01AG064802 · NIA · TORNADO THERAPEUTICS, INC. · PI Joan Mannick · fiscal years 2019 to 2023Named on NCT04584710
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:47 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed